BioWorld

Sep. 17, 2009

View Archived Issues

Neurocrine Snares $75M CEFF to Hunt for Products to License

Neurocrine Biosciences Inc. has secured a commitment from Kingsbridge Capital Ltd. to purchase shares in the company through a warrant-free equity financing that would provide up to $75 million over three years. (BioWorld Today) Read More

Pervasis Tackling PAD with $17M Round; Seeks Vascugel Partner

Read More

Commercialization Conundrum: Partnering vs. Building a FIPCO

Read More

Despite Concerns, Panel Favors Auxilium's Xiaflex in Dupuytren's

Read More

IPOs on Parade: Anthera Seeks $70M to Fund Cardio Studies

Read More

CMS Bundling Rule: Bad News for Amgen Now, Genzyme Later

Read More

Other News To Note

Read More

Clinic Roundup

Read More